Is Cannabis Biotech Zynerba the Hottest Post-IPO of 2015?

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) had a solid run on Monday following the prior week’s initial public offering. The problem is that this deal was so small, and it came out during a serious week of selling in the equities market, that most investors may not even know about this company at all.

Zynerba Pharmaceuticals sold 3 million shares of common stock at $14.00 per share in its IPO last week. All 450,000 shares in the overallotment option were used, and the pricing range had been $13.00 to $15.00 per share.

Jefferies and Piper Jaffray were the joint book-running managers for this offering. Canaccord Genuity and Oppenheimer were listed as co-managers for the IPO.

Here is what matters, after pricing at $14.00 the first day’s highest price was shown to be $22.25 – but the closing price was $16.25. Then shares closed at $19.32 on Thursday, followed by $24.54 on Friday....

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://247wallst.com/healthcare-business/2015/08/10/is-cannabis-biotech-zynerba-the-hottest-post-ipo-of-2015/